Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer - Sequist, L V; Besse, B; Lynch, T J (J Clin Oncol, 2010)
et al.